We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+7.65%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$8.27B
AUM Growth
+$1.17B
(+17%)
Cap. Flow
+$791M
Cap. Flow
% of AUM
9.57%
Top 10 Holdings %
Top 10 Hldgs %
43.67%
Holding
1,071
New
101
Increased
574
Reduced
272
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VanEck Gold Miners ETF
GDX
|
+$299M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$268M |
| 3 |
Apple
AAPL
|
+$63.9M |
| 4 |
Microsoft
MSFT
|
+$62.6M |
| 5 |
iShares China Large-Cap ETF
FXI
|
+$61.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$189M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$111M |
| 3 |
Visa
V
|
+$56.7M |
| 4 |
Mastercard
MA
|
+$48.1M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$41.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.46% |
| 2 | Financials | 14.83% |
| 3 | Healthcare | 4.08% |
| 4 | Consumer Discretionary | 3.56% |
| 5 | Industrials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Halozyme
HALO
$9.76B
| $1.93M | 0.02% |
73,351
+31,506
| +75% | +$877K |
|
|
CLVS
427
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.92M | 0.02% |
328,503
+187,227
| +133% | +$1.12M |
|
428
BioXcel Therapeutics
BTAI
$26.2M
| $1.91M | 0.02% |
2,760
+1,887
| +216% | +$1.42M |
|
429
First American
FAF
$7.7B
| $1.91M | 0.02% |
37,453
+15,125
| +68% | +$783K |
|
430
Franklin Resources
BEN
$17.9B
| $1.9M | 0.02% |
93,553
+37,595
| +67% | +$790K |
|
431
Neurocrine Biosciences
NBIX
$16.9B
| $1.9M | 0.02% |
19,766
+8,621
| +77% | +$997K |
|
432
UFP Industries
UFPI
$5.18B
| $1.9M | 0.02% |
33,619
+4,908
| +17% | +$277K |
|
433
Bank OZK
OZK
$5.65B
| $1.9M | 0.02% |
89,026
+20,927
| +31% | +$488K |
|
434
Alkermes
ALKS
$8.31B
| $1.89M | 0.02% |
114,032
+55,649
| +95% | +$1.01M |
|
435
Agios Pharmaceuticals
AGIO
$1.82B
| $1.88M | 0.02% |
53,671
+33,414
| +165% | +$1.46M |
|
436
Leidos
LDOS
$14.9B
| $1.88M | 0.02% |
21,050
+5,149
| +32% | +$465K |
|
437
CareDx
CDNA
$2.48B
| $1.87M | 0.02% |
49,378
+26,715
| +118% | +$902K |
|
|
EVA
438
DELISTED
Enviva Inc.
EVA
| $1.87M | 0.02% |
46,472
+2,274
| +5% | +$89.4K |
|
|
AJRD
439
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $1.86M | 0.02% |
46,695
+6,654
| +17% | +$269K |
|
440
Ligand Pharmaceuticals
LGND
$5.85B
| $1.86M | 0.02% |
31,254
+16,037
| +105% | +$1.09M |
|
441
Editas Medicine
EDIT
$407M
| $1.86M | 0.02% |
66,159
+32,685
| +98% | +$1.06M |
|
442
Coherus Oncology
CHRS
$222M
| $1.85M | 0.02% |
100,956
+41,571
| +70% | +$773K |
|
|
PACW
443
DELISTED
PacWest Bancorp
PACW
| $1.83M | 0.02% |
107,256
+28,403
| +36% | +$527K |
|
444
Erie Indemnity
ERIE
$12.4B
| $1.83M | 0.02% |
8,683
+3,494
| +67% | +$733K |
|
445
Louisiana-Pacific
LPX
$5.15B
| $1.82M | 0.02% |
61,726
+8,995
| +17% | +$276K |
|
|
VBIV
446
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $1.82M | 0.02% |
+21,198
| New | +$2.47M |
|
447
Zoetis
ZTS
$32.3B
| $1.81M | 0.02% |
10,963
-1,947
| -15% | -$299K |
|
448
Ionis Pharmaceuticals
IONS
$9.06B
| $1.81M | 0.02% |
38,179
+21,695
| +132% | +$1.21M |
|
449
BioCryst Pharmaceuticals
BCRX
$2.24B
| $1.81M | 0.02% |
526,302
+303,685
| +136% | +$1.3M |
|
450
Deere & Co
DE
$163B
| $1.8M | 0.02% |
+8,144
| New | +$1.57M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q3 2020 Portfolio in Review
As of Q3 2020, Rafferty Asset Management held 1,071 positions worth $8.27B, up 17% from $7.1B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Rafferty Asset Management deployed $791M of net new capital in Q3 2020, opening 101 new positions and adding to 574 existing holdings. Its largest new stake was INPHI CORPORATION: 63,139 shares worth $7.09M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $189M trimmed.
- Rafferty Asset Management's largest Q3 2020 buy was INPHI CORPORATION: 63,139 shares worth $7.09M.
- Rafferty Asset Management added most to VanEck Gold Miners ETF in Q3 2020, an estimated $299M increase.
- Rafferty Asset Management's biggest Q3 2020 reduction was iShares Russell 2000 ETF, cutting an estimated $189M.
- Rafferty Asset Management fully exited iShares Russell 1000 ETF in Q3 2020, selling an estimated $19.9M.
- Rafferty Asset Management's ten largest holdings make up 44% of its $8.27B portfolio in Q3 2020.
- Rafferty Asset Management opened 101 new positions and closed 122 in Q3 2020.
- Rafferty Asset Management's portfolio value rose 17% quarter-over-quarter to $8.27B.
Based on Rafferty Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.